Pharma Focus Asia

Dendreon Pharmaceuticals Invests in Contract Manufacturing and Patient Services for Cell Therapy Partners

Wednesday, June 16, 2021

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, has established and invested in its new contract manufacturing and services division to bring late-stage clinical assets through to commercialization. Leveraging its extensive manufacturing, process development and logistics expertise, Dendreon now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs.

“Innovative cell therapies have the potential to change how we treat serious diseases, but there is currently insufficient capacity to meet anticipated industry demand,” said Jason O’Neill, Chief Executive Officer of Dendreon. “With more than a decade of proven expertise in cell therapy manufacturing and an established supply chain and logistics infrastructure, we have invested in an offering that fills an immediate market need in this rapidly expanding field. This is a significant accomplishment for Dendreon and plays a key role in our future growth plans.”

Dendreon is one of only four companies manufacturing cell therapies for commercial use in the United States and began investing in dedicated capacity for later-stage partner programs within its existing infrastructure in early 2021. The company’s 180,000+ square foot cGMP-compliant and FDA approved manufacturing facility in Seal Beach, CA will serve as the contract manufacturing services hub. Its Seattle facility will serve as the process development and manufacturing sciences center.

“We are enabling the future of immunotherapy and supporting an unmet need in the market with immediate access to capacity and expertise,” said Maria Cho, Vice President of Business Development and Corporate Strategy. “We are looking to establish partnerships with biopharmaceutical companies developing CAR-Ts, autologous, or allogeneic cell therapies. Looking ahead, we plan to continue to leverage our core capabilities as a growth engine for our strategic partners and the industry as a whole.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024